Close

Puma Biotech (PBYI) Announces Encouraging Interim Data from PB272 Phase 2 Control Trial in HER2+ Breast Cancer

December 8, 2016 8:37 AM EST Send to a Friend
Puma Biotechnology, Inc. (NYSE: PBYI) announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login